New

2026 ZRA Tax Season: Filing deadline approaching — ensure your returns are submitted on time. Get tax compliance support →

M&J Consultants
  • Business Advisory

    Advisory Services

    • Business Consulting
    • Accounting & Bookkeeping
    • HR Consulting
    • Company Formation
    • Register from South Africa
    • Register from UK
    • Register from China
    • Investor Services

    Tax & Compliance

    • Tax Services
    • Tax Technology Consulting
    • Tax Legislation Advisory
    • All Tax Services
    Need Expert Advice?

    Free initial consultation with our team.

    +260 950 054 386 +260 979 369 374 [email protected]
    Schedule a Meeting →
  • Digital Transformation

    Enterprise Resource Planning

    • Odoo ERP System
    • Odoo for Manufacturing
    • Odoo for Retail
    • Odoo for NGOs
    • Odoo for Construction
    • Palladium ERP

    Business Systems

    • Sage Pastel Accounting
    • QuickBooks
    • Zoho Books
    • IQ Retail
    • Software for Mining
    • Software for Retail

    Payroll Software

    • Sage Pastel Payroll
    • Odoo Payroll
  • Tools

    Tax Calculators

    • PAYE Calculator 2026
    • VAT Calculator
    • NAPSA & NHIMA Calculator
    • DTA Navigator 2026

    Compliance Tools

    • Compliance Calendar 2026
    • Smart Invoice Checker
    • WHT Rate Finder
    • Turnover Tax Decision Tool
    • Import Duty Estimator
    Tools

    All calculations run in your browser. We never store your data.

    View All Tools →
  • Guides

    ZRA & Tax Compliance

    • PAYE Rates & Tax Bands 2026
    • VAT Registration Guide
    • Turnover Tax vs Income Tax
    • Smart Invoice Compliance
    • TPIN Registration
    • Tax Clearance Certificate
    • NAPSA & NHIMA Guide

    Company Formation

    • Register a Company (PACRA)
    • Registration for Foreigners
    • Registration Costs 2026

    HR & Employment

    • Payroll Setup Guide

    ERP & Software

    • Odoo Smart Invoice Setup
    • Best Accounting Software 2026

    More Resources

    • Insights & Articles
    • FAQ
    Expert Guides

    Comprehensive, Zambia-specific guides with real rates, deadlines, and step-by-step processes. Updated for 2026.

    Browse All Guides →
  • About Us
  • Contact Us
Get Started
Home / Insights / U.S. Health Aid Cuts to Zambia: Impact on the Phar...
Business Advisory 9 May 2025 7 min read

U.S. Health Aid Cuts to Zambia: Impact on the Pharmaceutical Sector

M&J Consultants M&J Consultants
U.S. Health Aid Cuts to Zambia: Impact on the Pharmaceutical Sector

The announcement on May 8, 2025, that the United States would sever US $50 million in annual health aid was more than just a news headline; it was a seismic event that sent a shockwave through the very foundation of Zambia’s public health system. This decision, a direct consequence of the “systematic theft” of donated medicines, is scheduled to take effect in January 2026. For a nation where American support, particularly through the President’s Emergency Plan for AIDS Relief (PEPFAR), has been the lifeblood of the HIV response for over two decades, the cut represents a profound and existential challenge.

However, within every crisis of this magnitude lies an equally powerful opportunity. This is not merely a financial gap to be plugged but a structural flaw to be rectified. The withdrawal of a key donor forces a national reckoning with deep-seated vulnerabilities that have long plagued the system—from a debilitating dependency on imports to the pervasive cancer of supply chain corruption. While the immediate risks to the health of millions of Zambians are severe and cannot be understated, the long-term view presents a powerful, albeit painful, pathway to transformation.

This is not a time for despair, but for design. Stakeholders across Zambia’s entire health ecosystem—from government ministries to private investors and frontline healthcare workers—must now pivot from reactive damage control to the proactive architecture of a more resilient, self-sufficient, and transparent pharmaceutical sector. This commentary serves as a strategic blueprint for navigating the aftershocks and leveraging this defining moment to build a stronger, more independent future.

The Unshakeable Pillar: Rebuilding Trust Through Radical Integrity

The core reason for this crisis—the rampant diversion and theft of medicines—must be the absolute central focus of the national response. Donor confidence, once shattered, is not rebuilt with placating press releases or promises of future action. It is earned through the rigorous and transparent implementation of systems that make theft impossible to hide and painful to attempt. The U.S. Embassy’s audit, which discovered that half of the surveyed private pharmacies were illegally selling government-funded stock, is a damning indictment that demands a revolutionary response in supply chain management.

Strategic Imperatives for Supply Chain Integrity:

  • Accelerate a Nationwide Digital “Glass Pipeline”: The current pilot of a digital stock-tracking system in 25 hospitals is a commendable first step, but the timeline and scope are now woefully inadequate. The government must reframe this initiative as a matter of urgent national security. The goal must be the rapid deployment of an end-to-end, fully interoperable “track-and-trace” system within the next 18 months. This is non-negotiable. This system needs to employ serialization—assigning a unique scannable code to every single box of medicine—and potentially leverage blockchain technology to create an immutable public ledger of every transaction. From the moment a shipment arrives at a ZAMMSA warehouse to the point it is dispensed to a patient in a rural clinic, it must be visible within this “glass pipeline.” Success hinges on user-friendly mobile interfaces for health workers and resolving challenges like data costs and connectivity in remote areas.

  • Deliver High-Profile Convictions, Not Scapegoats: While the 73 ongoing facility investigations are necessary, they will mean little if they only yield the arrests of low-level clinic staff. To restore trust, Zambia must demonstrate the political will to dismantle the entire criminal enterprise. This requires a sophisticated, multi-agency approach. The Anti-Corruption Commission, the Drug Enforcement Commission (DEC), and the Zambia Medicines Regulatory Authority (ZAMRA) must collaborate to “follow the money,” targeting the ringleaders and corrupt officials who facilitate this trade. The public and international partners need to see landmark convictions of powerful figures, sending an unequivocal message: the era of impunity is over.

  • Empower and Protect the Honest Majority: The most potent weapon against corruption is an empowered and protected workforce. The Ministry of Health and ZAMMSA must establish and resource truly independent internal audit functions with the mandate to conduct unannounced spot checks and publish their findings without political interference. Critically, a robust and genuinely anonymous whistleblower protection program must be launched and managed by an independent third party, such as a respected civil society organization. Providing legal protection and even financial rewards for credible tips will transform the thousands of honest healthcare workers into the guardians of the supply chain.

The Independence Agenda: Forging a New Path with Local Manufacturing

The US $50 million cut brutally exposes the fragility of a system that relies on imports for 85-90% of its pharmaceutical needs. This overwhelming dependency is a constant drain on precious foreign currency reserves, introduces significant risks of global supply chain disruptions, and leaves the nation’s health security subject to the shifting priorities of foreign governments. The “buy Zambian-made first” policy must urgently evolve from a political slogan into a core pillar of the nation’s economic and health strategy.

A Strategic Blueprint for Local Manufacturing:

  • Targeted Import Substitution: Zambia cannot and should not try to produce every drug it needs. The strategy must be laser-focused. The initial targets should be high-volume, relatively low-complexity products that address the largest public health burdens and represent the biggest import costs. This includes specific first-line antiretrovirals (ARVs) for the 1.2 million Zambians on treatment, common antimalarials, essential antibiotics, and increasingly, drugs for non-communicable diseases like metformin for diabetes and amlodipine for hypertension. These have predictable, high-volume demand, making them ideal candidates for local production.

  • Create “Pharma Parks” to De-Risk Investment: To attract serious investment, the government must lower the barriers to entry. This can be achieved by developing designated “pharma parks”—special economic zones tailored for the pharmaceutical industry. These parks would offer investors “plug-and-play” solutions: pre-approved land titles, reliable power and water infrastructure, shared effluent treatment plants, and on-site access to accredited quality control labs and ZAMRA regulatory support. This model, proven successful in countries like India and Egypt, dramatically reduces the upfront capital expenditure and bureaucratic hurdles for a new manufacturing entrant.

  • Leverage Government Procurement as a Catalyst: The single most powerful tool the government has is its purchasing power. ZAMMSA can issue long-term (3-5 year), guaranteed offtake agreements for specific, locally manufactured medicines. This guaranteed demand is the ultimate de-risking tool for an investor. It provides the revenue certainty needed to secure financing and invest in setting up a Good Manufacturing Practices (GMP)-compliant production line. This strategy directly converts the national drug budget into a powerful engine for industrialization.

The Private Sector: From Perceived Threat to Essential Partner

The explosive growth of private pharmacies—a 706% increase in retail licenses in just five years—is often viewed through the lens of risk, as it’s the primary marketplace for diverted public medicines. While this risk is real, a purely adversarial stance is a missed opportunity. If strategically engaged and properly regulated, this vibrant private sector can become an indispensable partner in enhancing efficiency, expanding access, and improving the quality of care for all Zambians.

Actionable Public-Private Partnership Models:

  • Co-location and Franchise Agreements: The Ministry of Health can pioneer partnerships where reputable private pharmacy chains operate outlets within public hospital premises. This model can be structured to handle the dispensing of both subsidized public medicines (tracked rigorously via the new digital system) and a wider range of private medicines. This improves patient choice, introduces private-sector efficiency in stock management, extends pharmacy operating hours, and creates a new, transparent revenue stream for cash-strapped public facilities.

  • Outsourcing Logistics to “Prime Vendors”: The public sector often struggles with the complexities of last-mile distribution. A “Prime Vendor” model could be piloted, where ZAMMSA contracts a single, accredited private logistics company to be responsible for the entire supply chain of a specific district or province. Payment would be tied to strict Key Performance Indicators (KPIs), such as on-time, in-full delivery rates and zero stock loss, all verified by the digital tracking system.

  • Fostering Collaborative Regulation: The role of ZAMRA must evolve from being a simple gatekeeper to a proactive market facilitator and quality enabler. This means working collaboratively with private pharmacy associations to co-develop and enforce ethical codes of conduct and standards of practice. By investing in capacity building and training for private pharmacists, ZAMRA can help foster a culture of self-regulation, turning the private sector into an ally in the fight for quality and integrity.

Conclusion: A Defining Choice for a Generation

The next 18 months will be a crucible for Zambia. The withdrawal of US $50 million in aid is not a glancing blow; it is a deep cut that will test the nation’s resolve. The immediate priority must be to mitigate the harm to the more than one million people whose lives depend on these supply chains.

But beyond the immediate crisis lies a generational choice. Zambia can choose to see this as a moment of victimhood, seeking to patch the funding gap while leaving the flawed structures in place. Or, it can seize this as a moment of agency. It can be the catalyst that finally breaks the debilitating cycle of dependency and corruption.

This is the time for bold, decisive leadership from the government. It is a time for savvy, long-term vision from investors. And it is a time for renewed partnership from the international community, shifting support from commodities to capacity-building. By embracing radical transparency, championing local industry, and forging innovative partnerships, Zambia can transform this shockwave of a crisis into a springboard for a stronger, healthier, and more sovereign future. The narrative of 2026 is not yet written; it will be defined by the courage and ingenuity of the choices made today.

Share This Article

Need Expert Advice?

Tell us what you need - a consultant will get back to you within 24 hours.

Get Zambia Business Insights in Your Inbox

Join business owners and investors who receive our weekly tax tips, compliance updates, and growth strategies. No spam - just actionable advice.

Unsubscribe anytime. We respect your privacy.

Related Articles

A Foreign Investor’s Guide to Zambia’s Private Healthcare Sector: Compliance, Licenses, and Profit Models
Business Advisory 4 min read

A Foreign Investor’s Guide to Zambia’s Private Healthcare Sector: Compliance, Licenses, and Profit Models

Zambia presents compelling opportunities for foreign investors in the private healthcare sector. Gap...

Building a Sustainable Business: Strategies for Supplying Medical Drugs Amidst Africa’s Healthcare Challenges
Business Advisory 4 min read

Building a Sustainable Business: Strategies for Supplying Medical Drugs Amidst Africa’s Healthcare Challenges

Building a sustainable business in Africa’s medical drug supply sector is both a noble mission and a...

Entering Zambia’s Medical Supply Chain: How Foreign Companies Can Supply Public Hospitals and Clinics
Business Advisory 3 min read

Entering Zambia’s Medical Supply Chain: How Foreign Companies Can Supply Public Hospitals and Clinics

Zambia’s public hospitals and clinics purchase more than 80 percent of their medicines, consumables,...

M&J Consultants

Building Timeless Businesses. Zambia's premier business consultancy firm offering expert advisory, tax, accounting, and enterprise solutions from our Lusaka office.

Services

  • Business Advisory
  • Accounting & Bookkeeping
  • Tax Consultancy
  • HR Consulting
  • Enterprise Solutions
  • Company Formation

Tools

  • Compliance Calendar 2026
  • PAYE Calculator 2026
  • VAT Calculator
  • NAPSA & NHIMA Calculator
  • Smart Invoice Checker
  • WHT Rate Finder
  • Turnover Tax Tool
  • Import Duty Estimator

Guides

  • PAYE Tax Guide 2026
  • VAT Guide Zambia
  • Turnover Tax Guide
  • Smart Invoice Guide
  • Company Registration
  • Payroll Setup Guide
  • Insights & Articles

Company

  • About Us
  • Contact Us
  • FAQ
  • DTA Navigator
  • Investor Services

Contact Info

  • 1504 Mungulube Road, Northmead, Lusaka, Zambia
  • [email protected]
  • [email protected]
  • +260 950 054 386
  • +260 979 369 374

© 2026 M&J Consultants. All rights reserved. | Lusaka, Zambia